Phadia Allergy and Autoimmunity Products Commercially Approved in India

By Phadia, PRNE
Sunday, December 19, 2010

UPPSALA, Sweden, December 20, 2010 - Import, sales and distribution of Phadia's allergy, asthma and
autoimmunity diagnostics products, including ImmunoCAP and EliA, have been
commercially approved by the Indian authorities.

(Logo: )

Following official approval, Phadia will begin marketing a broad
portfolio of diagnostic products to major commercial laboratories, hospitals
and research institutes as well as to individual physicians.

"The Indian market is strategically important to Phadia with high
economic growth and an expanding middle class demanding new and better
healthcare solutions," says Jean Forcione, Chief Operating Officer, PhadiaAB.

With allergy prevalence estimated at over 30 per cent of the Indian
population of 1.2bn people and the laboratory market expected to grow close
to 20 per cent, Phadia sees substantial growth potential.

Phadia opened its own subsidiary in India in April 2010 and already works
closely with several of the major commercial laboratories and major private
hospital chains.

About Phadia

PhadiaAB is a global leader in allergy, asthma and autoimmunity
diagnostics. Phadia develops, manufactures and markets complete blood test
systems to manage and support clinical diagnosis. Phadia has marketing
companies in more than 20 countries and distributors in more than 60
countries. Phadia is owned by the leading European buyout firm Cinven. For
more information please visit

    Media Contact:

    Ulf Bladin
    VP Marketing, Corporate Communication, Scientific Affairs
    Tel. +46-73-800-24-88


Media Contact: Ulf Bladin, VP Marketing, Corporate Communication, Scientific Affairs, Tel. +46-73-800-24-88, ulf.bladin at

Pharmaceuticals News

December 20 News

will not be displayed